Veraxa Biotech Holding AG正积极推进其新型双特异性抗体药物偶联物(ADC)项目Vxa-222。这一里程碑式的进展,源自其与OmniAb共同开展的发现合作。
Veraxa Biotech Holding AG正积极推进其新型双特异性抗体药物偶联物(ADC)项目Vxa-222。这一里程碑式的进展,源自其与OmniAb共同开展的发现合作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.